Myocardial infarction results in loss of cardiomyocytes (structural cells of the hearth), scar formation, ventricular remodeling, remodeling and eventually heart failure.
The use of stem cells has emerged as a potential new strategy for patients with ischemic heart disease. This includes bone marrow derived stem cells.
Transplantation of vascular cells derived from human induced pluripotent stem cells mobilized endogenous stem cells into the damaged zone, attenuated regional wall stress, stimulated neovascularization, and improved blood flow, which in turn resulted in marked increases in contractile function.
There are studies with intracoronary infusion of autologous bone marrow derived stem cells in patients with acute or chronic myocardial infarction showing improvement of left ventricular function.
Use of Stem Cells represents an area of significant potential. An expanding clinical literature now exists involving the use of bone marrow-derived stem cells in the treatment of ischemic heart disease. These early studies appear to provide promising results in patient populations that include those with refractory angina, ischemic cardiomyopathy with left ventricular dysfunction, and end-stage heart failure.
Cell based therapies using stem cells from bone marrow and the heart itself have demonstrated some promise. Accordingly, autologous stem and progenitor cells can be used safely in humans, and suggest that they may improve relevant clinical parameters in patients with heart disease.
Two specific cell populations that are particularly promising are the bone marrow derived mesenchymal stem cell and the heart muscle derived cardiac stem cells. Therapies have shown significant improvements in ventricular pump function, ventricular remodeling, myocardial perfusion, exercise capacity and clinical symptoms, compared to conventional treatment. The mechanisms behind the potential regenerative capacity of stem cells could be the replacement of the myocardium o blood vessels by trans-differentiation or an effect of substances produced by the stem cells on resident cells within the hearth.
The treatment regimes using bone marrow or adipose tissue derived stem cell solutions have all been safe. Stem Cells Transplant Institute wants to make it possible to move forward for a more individual and personalized stem cell treatment strategy in patients with this kind of needs, providing a secure environment and excellent human resource.